Ke-jing Tang
Guangzhou, 510080, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH).
Journal: Cancer biology & medicine
Published: May 22, 2026
Posaconazole mitigates α-amanitin-induced liver injury by inhibiting STT3B-mediated glycosylation and cellular uptake.
Journal: Frontiers in pharmacology
Published: April 24, 2026
Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial.
Journal: Clinical lung cancer
Published: March 20, 2026
Donor and recipient genetic polymorphisms modulate tacrolimus pharmacokinetics during voriconazole co-therapy: a drug-drug interaction study in liver transplant recipients.
Journal: Therapeutic advances in drug safety
Published: October 03, 2025
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.
Journal: Targeted oncology
Published: September 02, 2025
Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China.
Journal: Lung Cancer (Auckland, N.Z.)
Published: July 21, 2025
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).
Journal: Nature communications
Published: June 21, 2025
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 17, 2025
Analysis of pulmonary adverse events associated with immune checkpoint inhibitors based on FAERS and VigiBase database.
Journal: European journal of pharmacology
Published: February 27, 2025
Simultaneous Determination of Osimertinib and its Metabolites in Human Plasma for Clinical Applications Using High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Journal: Therapeutic drug monitoring
Published: January 08, 2025
The management of imatinib-associated severe skin rash in gastrointestinal stromal tumor: desensitization therapy and pharmacogenetic investigation.
Journal: The oncologist
Published: November 19, 2024
Liquid chromatography-tandem mass spectrometry for the quantification of ripretinib and its metabolites DP-5439 in human plasma.
Journal: Frontiers in pharmacology
Published: October 08, 2024
Last Updated: 09/26/2026